Anlongmed Fund is focused on early-stage investments in the life sciences and healthcare-related fields.
Business Model:
Revenue: $0
Employees: 0-0
Address:
City:
State:
Zip:
Country:
AnlongMed is a venture capital fund focuses on early stage life science and healthcare sectors. It is managed by a team led by Dr. Adam Zhao Chunlin, a veteran in life science with 30 years of experience, along with professionals with MNC, R&a;D, clinical, entrepreneurial and investment experience in both U.S. and China. The fund is anchored by Chinese Academy of Sciences. With extensive experience and connections from Chinese Academy of Sciences, Tsinghua University, Peking Union Medical College, and Bayhelix Group, AnlongMed strives to help entrepreneurs to start a venture in life science and healthcare in China. The fund has invested 22 firms from its first phase, including Netvation, a joint initiative toward new drug development between Chinese Academy of Science and Pfizer, Inc, 4 companies founded together with entrepreneurs across life science, biopharmaceutical, medical devices, and healthcare services.
Contact Phone:
Contact Email:
Announced Date | Company | Transaction | Money Raised |
---|---|---|---|
3/2016 | FitSAMO | Series A | - |
9/2017 | Hanyu Medical | Series A | - |
6/2020 | Sophonix | Series B | 14.2M |
8/2019 | Zhenzhun Biotech | Series A | - |
6/2018 | Laekna Therapeutics | Series A | 0 |
5/2018 | Jun Hui Biotech | Seed Round | - |
11/2016 | Connect Biopharmaceuticals | Seed Round | 5M |
9/2017 | Sonmol | Series A | 1.5M |
1/2021 | Skynor Medical | Series B | - |
1/2021 | Skynor Medical | Series B | - |
6/2020 | Sophonix | Series B | 0 |
8/2019 | Zhenzhun Biotech | Series A | - |
6/2018 | Laekna Therapeutics | Series A | 0 |
5/2018 | Jun Hui Biotech | Seed Round | - |
9/2017 | Sonmol | Series A | 0 |
9/2017 | Hanyu Medical | Series A | - |
11/2016 | Connect Biopharmaceuticals | Seed Round | 0 |
3/2016 | FitSAMO | Series A | - |
Name | Price |
---|
Name | Size | Announced Date |
---|